Literature DB >> 16804549

Reduced cerebral blood flow but elevated cerebral glucose metabolic rate in erythropoietin overexpressing transgenic mice with excessive erythrocytosis.

Thomas Frietsch1, Martin H Maurer, Johannes Vogel, Max Gassmann, Wolfgang Kuschinsky, Klaus F Waschke.   

Abstract

To examine the impact of excessive erythrocytosis on local cerebral blood flow (CBF) and cerebral glucose metabolic rate (CMR(glc)), we made use of our constitutively erythropoietin (Epo)-overexpressing transgenic mouse line (tg-6) that reach a mean hematocrit of 0.87. Compared with wild-type (wt) control siblings, CBF decreased by 44% in tg-6 mice, while upon hemodilution (tg-6-HD) to a physiologic hematocrit (e.g., 0.44) tg-6-HD mice returned the CBF to wt levels. Cerebral blood flow was determined in another transgenic mouse line that overexpresses human Epo in the brain only (tg-21): CBF increased by 17% compared with wt controls. However, oxygen delivery was similar in all four mouse groups tested (wt, tg-6, tg-6-HD and tg-21). Mean CMR(glc) was higher in tg-6 (+72%), tg-6-HD mice (+43%) and tg-21 (+22%) than in wt mice. Local CMR(glc) was higher in all 40 brain regions in tg-6 but only in 15 and 8 regions in tg-6-HD and tg-21 mice. These results show that prolonged increases in hematocrit did not alter cerebral oxygen delivery at a decreased CBF and increased CMR(glc). Hemodilution suggests that high blood viscosity is a cause of the decrease in CBF and partly of the increase in CMR(glc). Cerebral glucose metabolic rate may also be increased by a direct effect of Epo in the brain (tg-21 mice).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804549     DOI: 10.1038/sj.jcbfm.9600360

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  17 in total

1.  Thermodynamic constraints on neural dimensions, firing rates, brain temperature and size.

Authors:  Jan Karbowski
Journal:  J Comput Neurosci       Date:  2009-05-05       Impact factor: 1.621

Review 2.  Erythropoietin and diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  World J Diabetes       Date:  2015-10-25

3.  Excessive erythrocytosis compromises the blood-endothelium interface in erythropoietin-overexpressing mice.

Authors:  Vincent Richter; Michele D Savery; Max Gassmann; Oliver Baum; Edward R Damiano; Axel R Pries
Journal:  J Physiol       Date:  2011-08-22       Impact factor: 5.182

4.  Reversible abnormal functional neuroimaging presentations in polycythemia vera with chorea.

Authors:  Hui-Chun Huang; Yu-Chin Wu; Lee-Yung Shih; Woei-Chung Lo; Chon-Haw Tsai; Woei-Cherng Shyu
Journal:  J Neurol       Date:  2011-05-11       Impact factor: 4.849

Review 5.  New strategies for Alzheimer's disease and cognitive impairment.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

Review 6.  Raves and risks for erythropoietin.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang
Journal:  Cytokine Growth Factor Rev       Date:  2008-03-04       Impact factor: 7.638

7.  Simultaneous and noninvasive imaging of cerebral oxygen metabolic rate, blood flow and oxygen extraction fraction in stroke mice.

Authors:  Xiao-Hong Zhu; James M Chen; Tsang-Wei Tu; Wei Chen; Sheng-Kwei Song
Journal:  Neuroimage       Date:  2012-09-18       Impact factor: 6.556

Review 8.  Erythropoietin and oxidative stress.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Curr Neurovasc Res       Date:  2008-05       Impact factor: 1.990

Review 9.  Oxidative stress: Biomarkers and novel therapeutic pathways.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Exp Gerontol       Date:  2010-01-11       Impact factor: 4.032

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.